Hpgc Renmintongtai Pharmaceutical Corporation Reports Q3 Earnings: Net Profit Declines 45.69% Year-on-Year

Stock News2025-10-20

Hpgc Renmintongtai Pharmaceutical Corporation (600829.SH) has disclosed its third-quarter report for 2025, revealing that the company's revenue for the first three quarters reached 7.846 billion yuan, an increase of 2.19% year-on-year. The net profit attributable to shareholders of the listed company was 112 million yuan, a decline of 45.69% compared to the previous year; the net profit excluding non-recurring items was 110 million yuan, down 42.68% year-on-year; and the basic earnings per share stood at 0.1929 yuan. The decline in net profit is mainly attributed to: first, a year-on-year decrease in gross profit due to ongoing impacts from policies such as centralized procurement in the wholesale sector, which have tightened gross profit margins; second, operating expenses fluctuating in line with sales changes; and third, an increase in provisions for bad debts based on aging accounts receivable.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment